Overview

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

- Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy in postmenopausal patients with advanced breast cancer who received previous anti-estrogen treatment - To investigate changes in blood drug concentrations and blood hormone kinetics. - To investigate gene polymorphisms of CYP2A6, an enzyme involved in the metabolism of letrozole

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Chugai Pharmaceutical

Treatments:

Estrogen Antagonists
Estrogen Receptor Modulators
Estrogens
Letrozole